Inovio Pharmaceuticals - INO Stock Forecast, Price & News

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. The company engages in conducting and planning clinical studies of its DNA medicines for HPV-associated precancers, including cervical, vulvar, and anal dysplasia; HPV-associated cancers, such as head and neck, cervical, anal, penile, vulvar, and vaginal; other HPV-associated disorders, including recurrent respiratory papillomatosis; glioblastoma multiforme; prostate cancer; HIV; Ebola; Middle East Respiratory Syndrome (MERS); and Lassa fever. Its partners and collaborators include ApolloBio Corp., AstraZeneca, Beijing Advaccine Biotechnology Co., Ltd., The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations (CEPI), Defense Advanced Research Projects Agency (DARPA), Department of Defense (DoD), HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, Medical CBRN Defense Consortium (MCDC), National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Ology Bioservices, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Thermo Fisher Scientific, University of Pennsylvania, Walter Reed Army Institute of Research, and The Wistar Institute. The company has an agreement with Richter-Helm BioLogics GmbH & Co. KG to support investigational DNA vaccine INO-4800 for COVID-19; and a partnership with International Vaccine Institute and Seoul National University Hospital. The company was founded in 1979 and is headquartered in Plymouth Meeting, Pennsylvania.

Analysts Set New Price Targets

A number of research firms have recently weighed in on INO. Cantor Fitzgerald lowered their price target on shares of Inovio Pharmaceuticals from $6.00 to $3.00 in a report on Wednesday, May 11th. StockNews.com upgraded shares of Inovio Pharmaceuticals to a "sell" rating in a report on Monday, May 23rd. Royal Bank of Canada began coverage on shares of Inovio Pharmaceuticals in a report on Tuesday, July 19th. They issued a "sector perform" rating and a $4.00 price target on the stock. Finally, Oppenheimer cut shares of Inovio Pharmaceuticals from an "outperform" rating to a "market perform" rating in a report on Wednesday, May 11th. One research analyst has rated the stock with a sell rating and five have assigned a hold rating to the company's stock. Based on data from MarketBeat.com, Inovio Pharmaceuticals presently has a consensus rating of "Hold" and an average target price of $5.75.

Inovio Pharmaceuticals Stock Performance

Shares of Inovio Pharmaceuticals stock traded up $0.17 during midday trading on Friday, hitting $2.63. The company had a trading volume of 6,525,870 shares, compared to its average volume of 6,379,305. The stock has a market cap of $655.92 million, a price-to-earnings ratio of -1.63 and a beta of 0.88. The company has a quick ratio of 6.74, a current ratio of 3.18 and a debt-to-equity ratio of 0.06. The company has a fifty day simple moving average of $1.96 and a 200 day simple moving average of $2.67. Inovio Pharmaceuticals has a 12-month low of $1.38 and a 12-month high of $9.74.

Inovio Pharmaceuticals (NASDAQ:INO - Get Rating) last announced its quarterly earnings data on Tuesday, August 9th. The biopharmaceutical company reported ($0.46) EPS for the quarter, missing the consensus estimate of ($0.28) by ($0.18). The company had revenue of $0.78 million during the quarter, compared to analysts' expectations of $0.52 million. Inovio Pharmaceuticals had a negative net margin of 16,775.78% and a negative return on equity of 94.19%. The business's revenue for the quarter was up 187.5% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.39) earnings per share. As a group, analysts predict that Inovio Pharmaceuticals will post -1.28 earnings per share for the current fiscal year.

Insider Activity at Inovio Pharmaceuticals

In other Inovio Pharmaceuticals news, Director David B. Weiner sold 11,875 shares of the firm's stock in a transaction that occurred on Thursday, August 11th. The shares were sold at an average price of $2.66, for a total transaction of $31,587.50. Following the completion of the transaction, the director now directly owns 892,625 shares of the company's stock, valued at approximately $2,374,382.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. 3.30% of the stock is currently owned by insiders.